About Us

Dr Mark Bond did his PhD at the University of Bristol, under the supervision of Prof. Andrew Newby. His PhD research focussed on the transcriptional regulation of matrix metalloproteinase (MMPs) by mitogens and inflammatory cytokines and highlighted a major role of the NF-kB transcription factor in the upregulation of MMP-1, -3 and -9. Since then Dr Bond has 30 years of post-doc research experience in the field of cardiovascular molecular cell biology.

His research group focuses on uncovering the molecular mechanisms that drive cardiovascular disease and related conditions. Combining computational modelling, molecular cell biology, and experimental approaches, the team works to identify and characterise novel therapeutic targets, with a particular emphasis on transcriptional regulation and cell signalling pathways.

A key interest of the group lies in its integration of in silico drug discovery with laboratory validation, enabling the rapid development of innovative small molecules with potential clinical applications. Through interdisciplinary collaboration, the Bond Lab aims to translate fundamental scientific insights into tangible advances in treatment, contributing to improved outcomes for patients with cardiovascular and other chronic diseases.

Please look at the list of our publications for more details on our research.